FENC
Fennec Pharmaceuticals Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
+14/100
Last price
10.35
▼ 0.27 (2.54%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
10.62
Day high
10.66
Day low
10.15
Volume
99.08K
Market cap
$362.95M
P/E (TTM)
—
52W range
5.65 – 13.25
Trailing performance
Returnvs SPY
1W
-4.17%
-6.1%
1M
-16.46%
-17.6%
3M
+0.98%
-3.5%
6M
+63.77%
+45.6%
YTD
+34.42%
+20.2%
1Y
+4.76%
-11.7%
3Y
+37.82%
-44.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on FENC open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-30.25K
Net selling
Buy transactions
38
130.76K shares
Sell transactions
9
161.02K shares
Net transactions
+47
Buys less sells
Sell : buy shares
1.2 : 1
Mixed
Insider-held shares
4.95M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 30, 26 | HACKMAN JEFFREY S Chief Executive Officer |
STOCK | 1.16K | $0 | Direct |
| Sep 30, 26 | EVANS TERRY L Officer |
STOCK | 168 | $0 | Direct |
| Sep 30, 26 | SAYAD PIERRE SARGIS PH.D. Officer |
STOCK | 168 | $0 | Direct |
| Sep 15, 26 | BRUGHERA MARCO MARIA Director |
CONVERSION | 15.54K | $32.80K | Direct |
| Sep 15, 26 | BRUGHERA MARCO MARIA Director |
SELL | 15.54K | $159.96K | Direct |
| Sep 1, 26 | RAYKOV ROSTISLAV CHRISTOV Former |
SELL | 10.00K | $121.10K | Direct |
| Aug 31, 26 | ANDRADE ROBERT C Chief Financial Officer |
STOCK | 1.70K | $0 | Direct |
| Aug 31, 26 | HACKMAN JEFFREY S Chief Executive Officer |
STOCK | 1.16K | $0 | Direct |
| Aug 31, 26 | CIOFFI CHRISTIANA MARIE Officer |
STOCK | 156 | $0 | Direct |
| Aug 31, 26 | EVANS TERRY L Officer |
STOCK | 168 | $0 | Direct |
| Aug 31, 26 | SAYAD PIERRE SARGIS PH.D. Officer |
STOCK | 168 | $0 | Direct |
| Aug 31, 26 | RAYKOV ROSTISLAV CHRISTOV Former |
STOCK | 2.78K | $0 | Direct |
| Aug 31, 26 | SAYAD PIERRE SARGIS PH.D. Officer |
SELL | 12.00K | $146.16K | Direct |
| Aug 28, 26 | ANDRADE ROBERT C Chief Financial Officer |
CONVERSION | 21.93K | $111.83K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANDRADE ROBERT C |
Chief Financial Officer | 241.31K | Stock Award(Grant) |
BRUGHERA MARCO MARIA |
Director | 0 | Conversion of Exercise of derivative security |
CIOFFI CHRISTIANA MARIE |
Officer | 24.64K | Stock Award(Grant) |
EVANS TERRY L |
Officer | 21.69K | Stock Award(Grant) |
HACKMAN JEFFREY S |
Chief Executive Officer | 67.46K | Stock Award(Grant) |
RALLIS CHRISTOPHER ANIGERON |
Director | 63.08K | Conversion of Exercise of derivative security |
RAYKOV ROSTISLAV CHRISTOV |
Former | 124.41K | Sale |
SAYAD PIERRE SARGIS PH.D. |
Officer | 9.69K | Stock Award(Grant) |
SOUTHPOINT CAPITAL ADVISORS, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
Fundamentals
Market cap$362.95M
Enterprise value$321.70M
Revenue (TTM)$59.22M
Gross profit$55.51M
EBITDA$-1.02M
Net income$-3.25M
EPS (TTM)$-0.12
Free cash flow$1.07M
Total cash$41.25M
Total debt$0
Book value / share$1.21
Shares outstanding35.07M
Float19.88M
Short % of float1.80%
Dividend yield0.00%
Beta (5Y)1.23
Valuation & profitability ratios
Trailing P/E—
Forward P/E10.92
PEG ratio1.47
Price / sales—
Price / book8.55
EV / revenue5.43
EV / EBITDA-314.98
Gross margin93.73%
Operating margin9.72%
Profit margin-5.49%
Return on equity-18.58%
Return on assets-1.17%
Debt / equity—
Current ratio5.85
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $44.64M | $47.54M | $21.25M | $1.53M | -6.1% |
| Operating revenue | $44.64M | $47.54M | $21.25M | $1.53M | -6.1% |
| Cost of revenue | $3.76M | $3.18M | $1.26M | $86.00K | +18.2% |
| Gross profit | $40.88M | $44.35M | $19.99M | $1.45M | -7.8% |
| Research & development | $250.00K | $307.00K | $56.00K | $3.53M | -18.6% |
| Selling, general & admin | $46.91M | $41.48M | $32.71M | $20.51M | +13.1% |
| Total operating expense | $47.22M | $41.88M | $33.05M | $24.19M | +12.8% |
| Operating income | -$6.35M | $2.48M | -$13.06M | -$22.74M | -356.0% |
| Net interest income | -$1.29M | -$2.39M | -$2.95M | -$783.00K | +45.8% |
| Pre-tax income | -$9.63M | -$71.00K | -$16.05M | -$23.71M | -13,470.4% |
| Tax provision | $106.00K | $365.00K | $0 | — | -71.0% |
| Net income | -$9.74M | -$436.00K | -$16.05M | -$23.71M | -2,134.2% |
| Net income to common | -$9.74M | -$436.00K | -$16.05M | -$23.71M | -2,134.2% |
| Basic EPS | -0.35 | 0.00 | -0.60 | -0.90 | — |
| Diluted EPS | -0.35 | 0.00 | -0.60 | -0.90 | — |
| EBIT | -$7.55M | $4.00M | -$12.65M | -$22.74M | -289.0% |
| EBITDA | -$7.45M | $4.80M | -$12.36M | -$22.59M | -255.3% |
| Basic shares | 28.58M | 27.29M | 26.57M | 26.27M | +4.7% |
| Diluted shares | 28.58M | 27.29M | 26.57M | 26.27M | +4.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $36.79M | $26.63M | $13.27M | $23.77M | — | +38.1% |
| Cash & short-term investments | $36.79M | $26.63M | $13.27M | $23.77M | — | +38.1% |
| Accounts receivable | $23.22M | $12.88M | $8.81M | $1.54M | — | +80.2% |
| Inventory | $1.56M | $1.06M | $2.16M | $576.00K | — | +47.6% |
| Total current assets | $67.04M | $44.12M | $26.86M | $26.73M | — | +51.9% |
| Total assets | $70.55M | $44.95M | $26.86M | $26.94M | — | +57.0% |
| Total current liabilities | $10.52M | $6.92M | $7.55M | $4.61M | — | +52.0% |
| Long-term debt | — | $19.34M | $30.93M | $24.90M | $4.99M | — |
| Total debt | $0 | $19.34M | $30.95M | $24.90M | — | -100.0% |
| Retained earnings | -$229.42M | -$219.68M | -$219.25M | -$203.20M | — | -4.4% |
| Shareholder equity | $35.47M | -$5.87M | -$11.62M | -$2.57M | — | +704.1% |
| Working capital | $56.52M | $37.20M | $19.30M | $22.12M | — | +51.9% |
| Net tangible assets | $35.47M | -$5.87M | -$11.62M | -$2.57M | — | +704.1% |
| Shares issued | 34.16M | 27.53M | 27.03M | 26.36M | — | +24.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$9.74M | -$436.00K | -$16.05M | -$23.71M | -2,134.2% |
| Depreciation & amortisation | $103.00K | $800.00K | $0 | — | -87.1% |
| Stock-based compensation | $7.03M | $5.06M | $5.35M | $4.09M | +39.0% |
| Change in working capital | -$12.04M | $16.94M | -$6.78M | $1.10M | -171.1% |
| Operating cash flow | -$12.47M | $26.98M | -$17.14M | -$18.06M | -146.2% |
| Financing cash flow | $22.63M | -$13.62M | $6.64M | $20.73M | +266.2% |
| Free cash flow | -$12.47M | $26.98M | -$17.14M | -$18.06M | -146.2% |
| End cash position | $36.79M | $26.63M | $13.27M | $23.77M | +38.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $17.87M | $15.11M | $13.78M | $12.46M | $9.65M | +18.3% |
| Operating revenue | $18.89M | $15.87M | $9.22M | $13.67M | $10.94M | +19.1% |
| Cost of revenue | $721.00K | $570.00K | $1.76M | $660.00K | $967.00K | +26.5% |
| Gross profit | $17.15M | $14.54M | $12.01M | $11.80M | $8.69M | +18.0% |
| Research & development | $118.00K | $49.00K | $20.00K | $29.00K | $107.00K | +140.8% |
| Selling, general & admin | $15.30M | $14.61M | $14.55M | $11.96M | $11.31M | +4.7% |
| Total operating expense | $15.42M | $14.66M | $14.59M | $12.00M | $11.42M | +5.2% |
| Operating income | $1.74M | -$119.00K | -$2.58M | -$201.00K | -$2.73M | +1,559.7% |
| Net interest income | $284.00K | $332.00K | -$80.00K | -$434.00K | -$436.00K | -14.5% |
| Pre-tax income | $2.02M | $201.00K | -$4.68M | -$638.00K | -$3.15M | +902.5% |
| Tax provision | $42.00K | — | — | — | $0 | — |
| Net income | $1.97M | $201.00K | -$4.79M | -$638.00K | -$3.15M | +881.6% |
| Net income to common | $1.97M | $201.00K | -$4.79M | -$638.00K | -$3.15M | +881.6% |
| Basic EPS | 0.06 | 0.01 | -0.17 | -0.02 | -0.11 | +500.0% |
| Diluted EPS | 0.05 | 0.01 | -0.17 | -0.02 | -0.11 | +400.0% |
| EBIT | $2.02M | $208.00K | -$4.37M | -$52.00K | -$2.56M | +870.2% |
| EBITDA | $2.04M | $234.00K | -$4.35M | -$26.00K | -$2.53M | +773.1% |
| Basic shares | 34.55M | 34.34M | 31.18M | 27.89M | 27.66M | +0.6% |
| Diluted shares | 36.43M | 35.55M | 31.18M | 27.89M | 27.66M | +2.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $41.25M | $40.18M | $36.79M | $21.95M | $18.70M | — | +2.7% |
| Cash & short-term investments | $41.25M | $40.18M | $36.79M | $21.95M | $18.70M | — | +2.7% |
| Accounts receivable | $23.27M | $18.76M | $23.22M | $19.34M | $17.50M | — | +24.0% |
| Inventory | $2.37M | $1.86M | $1.56M | $2.48M | $2.20M | — | +27.9% |
| Total current assets | $72.50M | $66.88M | $67.04M | $46.06M | $40.79M | — | +8.4% |
| Total assets | $75.75M | $71.82M | $70.55M | $49.26M | $44.88M | — | +5.5% |
| Total current liabilities | $12.39M | $9.59M | $10.52M | $9.81M | $8.41M | — | +29.3% |
| Long-term debt | — | — | — | $19.38M | $19.36M | $19.35M | — |
| Total debt | — | — | $0 | $19.38M | $19.36M | $19.35M | — |
| Total liabilities | $33.31M | $34.15M | $35.08M | $53.75M | $52.34M | — | -2.4% |
| Retained earnings | -$227.25M | -$229.22M | -$229.42M | -$224.64M | -$224.00M | — | +0.9% |
| Shareholder equity | $42.44M | $37.67M | $35.47M | -$4.49M | -$7.46M | — | +12.7% |
| Working capital | $60.11M | $57.29M | $56.52M | $36.25M | $32.38M | — | +4.9% |
| Net tangible assets | $42.44M | $37.67M | $35.47M | -$4.49M | -$7.46M | — | +12.7% |
| Shares issued | 35.03M | 34.54M | 34.16M | 28.06M | 27.62M | — | +1.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $1.97M | $201.00K | -$4.79M | -$637.00K | -$3.15M | +881.6% |
| Depreciation & amortisation | $25.00K | $26.00K | $26.00K | $26.00K | $25.00K | -3.8% |
| Stock-based compensation | $1.77M | $990.00K | $2.52M | $2.22M | $1.49M | +79.2% |
| Change in working capital | -$5.10M | $2.67M | -$6.31M | $1.54M | -$3.21M | -290.6% |
| Operating cash flow | $50.00K | $2.38M | -$5.96M | $1.49M | -$3.69M | -97.9% |
| Financing cash flow | $1.02M | $1.01M | $20.80M | $1.75M | -$284.00K | +0.8% |
| Free cash flow | $50.00K | $2.38M | -$5.96M | $1.49M | -$3.69M | -97.9% |
| End cash position | $41.25M | $40.18M | $36.79M | $21.95M | $18.70M | +2.7% |
Options analytics
Put / call volume
14.25
Put-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
2.50
-75.8% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
-9.4%
Calls bid over puts
Call volume
32
Contracts, this expiry
Put volume
456
Contracts, this expiry
Heaviest call OI
7.50
12 contracts
Heaviest put OI
2.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.02 | 0.05 | +127.3% |
| Mar 2026 | -0.02 | 0.01 | +160.0% |
| Dec 2025 | 0.04 | -0.10 | -350.3% |
| Sep 2025 | -0.03 | -0.02 | +20.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.11 | 5 | $18.91M | +51.7% |
| Next quarter | 0.14 | 5 | $20.68M | +50.1% |
| Current year | 0.32 | 5 | $72.56M | +62.5% |
| Next year | 0.95 | 5 | $103.11M | +42.1% |
Analyst targets & ownership
Mean target$17.67
High target$20.00
Low target$16.00
Implied upside70.69%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy2 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders14.13%
Held by institutions54.23%
Institutions holding146
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
10.56
-2.02% from price
SMA 20
10.74
-3.62% from price
SMA 50
11.15
-7.16% from price
SMA 100
10.54
-1.77% from price
SMA 200
8.96
+15.53% from price
EMA 12
10.62
-2.57% from price
EMA 26
10.87
-4.81% from price
EMA 50
10.86
-4.73% from price
RSI (14)
42.0
Neutral
MACD (12,26,9)
-0.25
Hist -0.04
ATR (14)
0.50
4.79% of price
Realised vol 30D
43.0%
Annualised
Bollinger upper
11.39
20, 2σ
Bollinger lower
10.09
20, 2σ
50 / 200 cross
Golden
11.15 vs 8.96
Trend bias
Above 200
+15.53%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.35
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
43.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-40.8%
Peak to trough
Max drawdown 5Y
-65.6%
Peak to trough
ATR 14
0.50
4.79% of price
Beta (reported)
1.23
5Y monthly, from filing
Short interest
Shares short
545.04K
Prior 532.10K
Change vs prior
+2.4%
Shorts adding
% of float
1.80%
Normal
% of shares out
1.55%
Against total outstanding
Days to cover
2.1
Liquid
Float
19.88M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 12, 26 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Aug 12, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| May 22, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 16, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jan 9, 26 | Piper Sandler | INITIATED | — | Overweight |
| Aug 21, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 15, 25 | Craig-Hallum | MAINTAINED | Buy | Buy |
| May 20, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 14, 25 | Craig-Hallum | MAINTAINED | Buy | Buy |
| Mar 11, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 17, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-17
Periodic Financial Reports
10-Q · 2026-08-13
Offering Registrations
S-8 · 2026-06-11
Corporate Changes & Voting Matters
8-K · 2026-06-10
Corporate Changes & Voting Matters
8-K · 2026-05-22
Corporate Changes & Voting Matters
8-K · 2026-05-18
Periodic Financial Reports
10-Q · 2026-05-14
Corporate Changes & Voting Matters
8-K · 2026-04-28
Headlines
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
GlobeNewswire · 20d ago
Fennec Pharmaceuticals (FENC) Stock Sees Fair Value Lift As Analysts Raise PEDMARK Views
Simply Wall St. · 54d ago
Fennec Pharmaceuticals Inc (FENC) (Q2 2026) Earnings Call Highlights: Record Sales and ...
GuruFocus.com · 57d ago
Fennec Pharmaceuticals at Multi-Year High After Swing to Q2 Earnings Beat
MT Newswires · 57d ago
Adherex Technologies Q2 Earnings Call Highlights
MarketBeat · 57d ago
Fennec Pharmaceuticals surges 8% as Q2 earnings and revenue beat estimates
InvestorsHub · 57d ago
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · 57d ago
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
GlobeNewswire · 63d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.